title: Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting.
abstract: This overview describes the goals and objectives of the third conference conducted as part of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative. This third conference was focused on selecting specific paradigms from cognitive neuroscience that measured the constructs identified in the first CNTRICS meeting, with the goal of facilitating the translation of these paradigms into use in clinical trials contexts. To identify such paradigms, we had an open nomination process in which the field was asked to nominate potentially relevant paradigms and to provide information on several domains relevant to selecting the most promising tasks for each construct (eg, construct validity, neural bases, psychometrics, availability of animal models). Our goal was to identify 1-2 promising tasks for each of the 11 constructs identified at the first CNTRICS meeting. In this overview article, we describe the on-line survey used to generate nominations for promising tasks, the criteria that were used to select the tasks, the rationale behind the criteria, and the ways in which breakout groups worked together to identify the most promising tasks from among those nominated. This article serves as an introduction to the set of 6 articles included in this special issue that provide information about the specific tasks discussed and selected for the constructs from each of 6 broad domains (working memory, executive control, attention, long-term memory, perception, and social cognition).
authors.affiliation: Washington University, St. Louis, MO, USA. dbarch@artsci.wustl.edu
authors.forename: Deanna M
authors.initials: DM
authors.lastname: Barch
authors.forename: Cameron S
authors.initials: CS
authors.lastname: Carter
authors.forename: Amy
authors.initials: A
authors.lastname: Arnsten
authors.forename: Robert W
authors.initials: RW
authors.lastname: Buchanan
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Cohen
authors.forename: Mark
authors.initials: M
authors.lastname: Geyer
authors.forename: Michael F
authors.initials: MF
authors.lastname: Green
authors.forename: John H
authors.initials: JH
authors.lastname: Krystal
authors.forename: Keith
authors.initials: K
authors.lastname: Nuechterlein
authors.forename: Trevor
authors.initials: T
authors.lastname: Robbins
authors.forename: Steven
authors.initials: S
authors.lastname: Silverstein
authors.forename: Edward E
authors.initials: EE
authors.lastname: Smith
authors.forename: Milton
authors.initials: M
authors.lastname: Strauss
authors.forename: Til
authors.initials: T
authors.lastname: Wykes
authors.forename: Robert
authors.initials: R
authors.lastname: Heinssen
mesh_terms: D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000209:etiology / Q000628:therapy; D019336:Cognitive Science; D006801:Humans; D009488:Neurosciences; D012559:Schizophrenia / Q000150:complications